Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety

Launched by TECHNISCHE UNIVERSITÄT DRESDEN · Nov 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a condition called postoperative hyperamylasemia (POH) that can occur after surgery to remove part of the pancreas (pancreatectomy). Researchers believe that high levels of a substance called amylase in the blood may help predict complications after surgery, particularly a condition known as postpancreatectomy acute pancreatitis (PPAP). The goal is to better understand how common this condition is and to improve the way it is classified and managed, which could lead to better care and outcomes for patients after their surgery.

To participate in this study, individuals should be between the ages of 18 and 85 and must be undergoing pancreatic surgery for either cancer or non-cancer conditions. Participants will be asked to give their consent to join the study. If you are selected, you can expect to undergo routine evaluations and tests to monitor your health after surgery. This research is essential for finding ways to improve patient safety and outcomes following pancreatic surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis
• • Patients aged 18-85 years
• • Willingness to participate as demonstrated by giving a written informed consent.
• Exclusion Criteria:
• • Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy
• • Age less than 18 years
• • Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts)
• • One-stage total pancreatectomy
• • Missing written consent